Nakayama, J, Edwards, J, Stine, JE, Pelkofski, E, Gehrlg, PA, Secord, AA, and Duska, LR. "Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary." May 20, 2014.
Angeles Alvarez Secord, MD
My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.
Education and Training
- Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
- M.D., University of Washington, 1994
- Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011
Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment.
Selected Grants and Awards
- Atezo NACT for Ovarian Cancer
- Lynparza Open Acess Olaparib
- GOG3015 Foundation Study ( Atezo Frontline)
- Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
- GOG3005-ABB VIE Protocol M13-694
- Quadra Study
- A Phase 2 Randomized Double-Blind Trial of Maintenance with Niraparib vs Placebo
- Apera ARP-407
- NCI National Clinical Trials Network U10 (Year 4)
- Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer
- Women with BRCA-mutated Advanced Stage Ovarian Cancer
- Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients
- Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer
- Tesaro Ovarian Cancer Practicum
- A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy
Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, S, Celia, D, Weinfurt, K, Abernethy, AP, and Reed, SD. "Relative influence of factors determining a woman's preference for treatment options in ovarian cancer." May 20, 2014.
Previs, RA, Kilgore, J, Craven, R, Broadwater, G, Bean, S, Wobker, S, DiFurio, M, Bae-Jump, V, Gehrig, PA, and Secord, AA. "Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 24, no. 4 (May 2014): 670-675.
Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: A single institution study of 458 patients." Gynecologic Oncology 133, no. 2 (May 2014): 211-215.
Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients." Gynecologic oncology 133, no. 2 (May 2014): 211-215.
Havrilesky, L, Secord, A, Ehrisman, J, Berchuck, A, Valea, F, Lee, P, Cella, D, Weinfurt, K, Abernethy, A, and Reed, S. "Relative Influence of Factors Determining a Woman’s Preference for Treatment Options in Ovarian Cancer: A Discrete Choice Experiment." May 2014.
Lee, PS, and Secord, AA. "Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway." Cancer Treatment Reviews 40, no. 4 (May 1, 2014): 507-512. (Review)
Lee, PS, and Secord, AA. "Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway." Cancer Treat Rev 40, no. 4 (May 2014): 507-512. (Review)
Ko, EM, Walter, P, Clark, L, Jackson, A, Franasiak, J, Bolac, C, Havrilesky, L, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, VL. "The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance." Gynecologic oncology 133, no. 1 (April 2014): 28-32.
Herzog, TJ, Monk, BJ, Rose, PG, Braly, P, Hines, JF, Bell, MC, Wenham, RM, Secord, AA, Roman, LD, Einstein, MH, Drake, RD, and Childs, BH. "A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube." Gynecologic oncology 132, no. 3 (March 2014): 517-525.